Abpro Holdings (ABP) Company Report

Abpro Holdings, Inc. and co-development partner Celltrion, Inc. announced on January 6, 2026, that the U.S. FDA cleared the Investigational New Drug (IND) application for their lead multispecific antibody cancer candidate, ABP-102 / CT-P72.
This clearance enables the initiation of a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABP-102 / CT-P72 in patients with HER2-positive solid tumors.
The clinical trial is anticipated to commence in the first half of 2026 and will be led by Celltrion as part of their joint strategic collaboration.
Preclinical data for ABP-102 / CT-P72 showed robust antitumor activity in HER2-high tumor models and was well tolerated in non-human primate toxicology studies, indicating potential for a differentiated therapeutic profile.

Jan 6, 2026, 12:06 PM

Abpro Holdings Submits IND for Phase 1 Clinical Trial of ABP-102/CT-P72

ABP

New Projects/Investments

Abpro Holdings, Inc. announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ABP-102/CT-P72 on December 15, 2025.
This IND aims to initiate a Phase 1 clinical trial for patients with HER2-positive cancers, including breast and gastric cancers.
The Phase 1 clinical trial is anticipated to begin in the first half of 2026 (1H 2026), pending regulatory clearance.
ABP-102/CT-P72 is a HER2 × CD3 T cell engager being co-developed by Abpro and Celltrion, Inc..
Preclinical studies for ABP-102/CT-P72 demonstrated enhanced HER2-high tumor selectivity and a favorable safety profile.

Dec 15, 2025, 12:16 PM

Abpro Holdings Receives Nasdaq Listing Extension

ABP

Delisting/Listing Issues

New Projects/Investments

Abpro Holdings (ABP) has been granted an extension by the Nasdaq Hearings Panel to regain full compliance with Nasdaq listing requirements.
The company's compliance roadmap includes a reverse stock split, which took effect on November 3, a market transfer application, and a planned capital strategy to increase stockholders' equity.
Abpro has access to up to $44 million in equity financing to fund operations and achieve long-term financial milestones.
The company has achieved an estimated ~60% reduction in operating expenses versus the prior year through disciplined streamlining.
Its lead antibody candidate, ABP-102, developed in partnership with Celltrion, is on track for first-in-human trials in 2026.

Dec 9, 2025, 12:00 PM

Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025

ABP

New Projects/Investments

Product Launch

Abpro Holdings, Inc. and Celltrion, Inc. will present new preclinical data for their co-developed CT-P72/ABP-102 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting from November 6-10, 2025.
The poster for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, was selected as one of the Top 150 abstracts out of more than 1,300 submissions.
Preclinical data demonstrates potent and selective anti-tumor activity in HER2-high models, including Enhertu-resistant tumors, and a favorable safety profile in non-human primates.
These findings support the advancement of CT-P72/ABP-102 toward first-in-human clinical studies for HER2-positive cancers, with plans to initiate trials next year.

Nov 4, 2025, 12:00 PM

Abpro Announces 1-for-30 Reverse Stock Split

ABP

Delisting/Listing Issues

Abpro Holdings, Inc. announced a 1-for-30 reverse stock split that became effective at 5:01 p.m. Eastern Time on October 31, 2025, with split-adjusted trading commencing on November 3, 2025.
This action will reduce the number of outstanding common shares from approximately 81.2 million to 2.7 million and is a necessary step to maintain Nasdaq listing compliance.
The company also reported achieving an estimated ~60% reduction in operating costs compared to the same period in 2024.

Nov 3, 2025, 12:00 PM

Get instant answers from SEC filings, earnings calls & more